Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage by Rogers, Stephen C et al.




Hypoxia modulates the purine salvage pathway and
decreases red blood cell and supernatant levels of
hypoxanthine during refrigerated storage
Stephen C. Rogers
Washington University School of Medicine in St. Louis
Allan Doctor
Washington University School of Medicine in St. Louis
et al.
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Rogers, Stephen C.; Doctor, Allan; and et al., ,"Hypoxia modulates the purine salvage pathway and decreases red blood cell and
supernatant levels of hypoxanthine during refrigerated storage." Haematologica.103,2. 361-372. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6735
haematologica | 2018; 103(2) 361
Received: August 11, 2017.
Accepted: October 24, 2017.
Pre-published: October 27, 2017.
©2018 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-
mercial purposes is not allowed without permission in writing
from the publisher.
Correspondence: 







Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/103/2/361
Hypoxanthine catabolism in vivo is potentially dangerous as it fuelsproduction of urate and, most importantly, hydrogen peroxide.However, it is unclear whether accumulation of intracellular and
supernatant hypoxanthine in stored red blood cell units is clinically rele-
vant for transfused recipients. Leukoreduced red blood cells from glu-
cose-6-phosphate dehydrogenase-normal or -deficient human volun-
teers were stored in AS-3 under normoxic, hyperoxic, or hypoxic condi-
tions (with oxygen saturation ranging from <3% to >95%). Red blood
cells from healthy human volunteers were also collected at sea level or
after 1-7 days at high altitude (>5000 m). Finally, C57BL/6J mouse red
blood cells were incubated in vitro with 13C1-aspartate or 13C5-adenosine
under normoxic or hypoxic conditions, with or without deoxyco-
formycin, a purine deaminase inhibitor. Metabolomics analyses were
performed on human and mouse red blood cells stored for up to 42 or
14 days, respectively, and correlated with 24 h post-transfusion red
blood cell recovery. Hypoxanthine increased in stored red blood cell
units as a function of oxygen levels. Stored red blood cells from human
glucose-6-phosphate dehydrogenase-deficient donors had higher levels
of deaminated purines. Hypoxia in vitro and in vivo decreased purine oxi-
dation and enhanced purine salvage reactions in human and mouse red
blood cells, which was partly explained by decreased adenosine
monophosphate deaminase activity. In addition, hypoxanthine levels
negatively correlated with post-transfusion red blood cell recovery in
mice and – preliminarily albeit significantly - in humans. In conclusion,
hypoxanthine is an in vitro metabolic marker of the red blood cell storage
lesion that negatively correlates with post-transfusion recovery in vivo.
Storage-dependent hypoxanthine accumulation is ameliorated by
hypoxia-induced decreases in purine deamination reaction rates.
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ABSTRACT
Introduction
Packed red blood cell (RBC) transfusions are life-saving
interventions for millions of recipients every year (~11.3
million units transfused/year in the USA alone1).
Refrigerated RBC storage is required to make the ~100 mil-
lion units collected worldwide every year available for
transfusion. However, refrigerated RBC storage induces
many biochemical and morphological alterations, collec-
tively termed the “storage lesion.”2–5 Some alterations are
promoted by oxidative stress, arising within the first 2
weeks of storage,6,7 targeting proteins,8–11 lipids,12–15 and vari-
ous small molecules, including purines.16–19 These observa-
tions, together with early depletion of high energy phos-
phate compounds, including adenosine triphosphate (ATP)
and 2,3-diphosphoglycerate (2,3-DPG), prompted many to
question whether the storage lesion compromises RBC
transfusion safety and efficacy. 
Despite evidence documenting the evolution and severity
of the storage lesion,2–4 whether prolonged RBC storage
duration adversely affects transfused recipients is debat-
able. Recent randomized clinical trials concluded that the
general standard of care would not be improved by exclu-
sively issuing fresh RBC, at least for the studied clinical indi-
cations and within the statistical power of these studies.20
However, these clinical trials did not examine blood that
was particularly old (e.g., >35 days). Recent evidence indi-
cates that the storage lesion does not develop linearly and
only transfusing >35-day old RBC induces increases in cir-
culating non-transferrin-bound iron in healthy recipients.21
In parallel, increases in adverse outcomes have been
observed in high-risk patients receiving blood units aged
>35 days.22 Thus, to the extent that in vivo hemolysis and
non-transferrin-bound iron are mediators of the adverse
effects of transfusion, the clinical trials to date have not
shown that transfusing old blood is safe. 
Current storage solutions make it possible to store RBC
for up to 42 days with an average ~17% loss of transfusion
potency at outdate,23 based on 51Cr-labeled post-transfusion
recovery (PTR) studies in healthy human volunteers,24
which provide information on the ability of RBC to circu-
late, but not necessarily their ability to deliver oxygen. This
is relevant when considering the effects of the loss of poten-
cy in massively transfused recipients, such as trauma
patients.23
Despite reassuring evidence from clinical trials, further
improvement in RBC storage strategies are possible, as
recommended by the US National Heart, Lung, and Blood
Institute.25 To this end, advances in the molecular under-
standing of the storage lesion have fostered the design of
novel storage solutions (e.g., alkaline additives26) and
strategies (e.g., hypoxic storage27) to improve storage qual-
ity. In parallel, recently identified “omics” markers of stor-
age age28–30 may prove useful for benchmarking potential
improvements in storage quality, once their association
with post-transfusion outcomes has been clearly demon-
strated. The present study addresses this by focusing on
hypoxanthine,17,28,31 a deaminated purine resulting from the
metabolism of ATP, adenosine monophosphate (AMP),
and adenosine in mature RBC. Recently, Casali et al.,31
Bordbar et al.16 and Paglia et al.28 reported that end-of-stor-
age SAGM RBC and supernatants are characterized by
levels of hypoxanthine as high as ~450 and 1000 mM,
respectively. As previously noted,31 under physiological
conditions the concentration of hypoxanthine is very low,
both inside erythrocytes (9.3 nM) and in human plasma
(1–8 mM). Transfusion of a single unit of end-of-storage
blood containing almost millimolar levels of hypoxan-
thine could thus result in circulating hypoxanthine levels
of ~100 mM, an amount that would further increase pro-
portionally to the number of older units transfused to the
recipient. Notably, concentrations as high as 100 mM are
used in cytotoxicity assays to produce toxic amounts of
hydrogen peroxide generated through the xanthine dehy-
drogenase/oxidase-catalyzed conversion of hypoxanthine
to urate.31
On this background, in the present study, we provide
absolute quantitative measurements of hypoxanthine in
cells and supernatants of AS-3 packed RBC. We report
negative correlations between RBC hypoxanthine levels in
vitro and PTR in vivo in 14 different mouse strains and, pre-
liminarily, in healthy human volunteers, indicating the
potential clinical relevance of this metabolic lesion. We
also provide a possible mechanistic explanation regarding
the role of AMP deaminase (AMPD) activation in human
and mouse RBC as a function of hemoglobin oxygen sat-
uration (SO2) and resulting oxidative stress in vitro and in
vivo. Finally, by combining state-of-the-art deep pro-
teomics, quantitative mass spectrometry (MS), tracing
experiments with stable isotope-labeled substrates, and
pharmacological inhibition of purine deaminases, we
identify the role of hypoxia in preventing AMPD activa-
tion, thereby decreasing the storage-dependent accumula-
tion of deaminated purines, particularly hypoxanthine.
Methods
Blood samples were collected from healthy donor volun-
teers upon receiving written informed consent and in con-
formity with the Declaration of Helsinki under the protocol
approved by the relative institutions, including the
University of Texas Houston and University of Colorado
Denver institutional review boards (n. AWC-14-0127 and
11-1581, respectively). Commercial reagents were pur-
chased from Sigma-Aldrich (Saint Louis, MO, USA) unless
otherwise noted. 
Glucose-6-phosphate dehydrogenase-normal and 
-deficient human red blood cells, stored under 
normoxic or hypoxic conditions  
Blood was collected from healthy glucose-6-phosphate
dehydrogenase (G6PD)-normal donors at the Bonfils Blood
Center (Denver, CO, USA) or from G6PD-deficient donors
(Mediterranean variant) in Athens (Greece) according to the
Declaration of Helsinki. Filter leukocyte-reduced (Pall
Medical, Braintree, MA, USA) packed RBC were stored in
CP2D-AS-3 (n=4; Haemonetics Corp., Braintree, MA, USA)
or CPD-SAGM (n=6). Units were sampled in a sterile man-
ner (15 mL per time point) on days 0, 21, 42, and cells and
supernatants were separated by centrifugation at 2000 x g
for 10 min at 4°C.  
Mouse red blood cell storage under normoxic and 
hypoxic conditions with an adenosine monophosphate
deaminase inhibitor 
RBC were collected aseptically by exsanguination from
C57BL/6J mice (pool of n=5 per group) and stored for 14
days32 in CPD-AS-3 under normoxic or hypoxic conditions
(O2 = 21% or 8%, respectively), in the presence or absence
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of 13C5-adenosine (5 mM) and deoxycoformycin (500 mM),
an AMPD  inhibitor (500 mM), as described.33
Post-transfusion recovery studies in healthy human donor
volunteers 
PTR studies were performed at Columbia University
Medical Center-New York Presbyterian Hospital in healthy
volunteers receiving autologous packed RBC (n=52), and
were previously published21 without accompanying
metabolomics data. Briefly, immediately before issue, a 25
mL sample of blood, obtained from the unit using a sterile
docking device, was radiolabeled with 51Cr,21 while a match-
ing 500 mL sample was immediately frozen for
metabolomics analyses. At 1-4 h after transfusion of the
unit, the 51Cr–labeled RBC sample was infused over 1 min.
Blood specimens were then obtained every 2.5 min
between 5 and 15 min after infusion and used to extrapo-
late time zero and the final time point to calculate PTR.21
Hypoxanthine levels were measured in the transfusates of
the subjects in the previously published study.21
Post-transfusion recovery studies in mice
The PTR studies in mice were performed as described
previously,34 using multiple strains from Jackson Labs (Bar
Harbor, ME, USA): KK/HIJ, LG/J, AKR/J, FVB/NJ, C3H/HeJ,
DBA/2J, NOD/ShiLtJ, 129X1/SvJ, 129S1/SvImJ, A/J, BTBR/
T+ tf/J, Balb/cByJ, C57Bl/6J. UbiC-GFP male mice, on a
C57BL/6 background, were bred to FVB/NJ females in the
Bloodworks NW Research Institute Vivarium (Seattle, WA,
USA) and offspring were used as transfusion recipients at
24-28 weeks of age.34
Human red blood cell oxygen saturation 8 hours 
after donation
CP2D-AS-3 RBC with controlled SO2 [i.e., >95% (hyper-
oxic) to <3% (hypoxic)] on day 0 were prepared in vented
chambers (Difco BLL, Detroit, MI, USA). SO2 levels in 977
RBC units at the Rhode Island Blood Center were deter-
mined within 8 h of donation and routine processing (i.e.
leukofiltration and storage in AS-3 under standard normox-
ic blood bank conditions), with methods previously
described and validated.35
High altitude studies 
RBC were collected from 12 male and nine female
healthy human volunteers at sea level or after 3 h (ALT1
am), >8 h (ALT1 pm), or 7 days (ALT7) of exposure to high
altitude hypoxia (5260 m) in Mt. Chacaltaya, Bolivia, with-
in the framework of the AltitudeOmics study.36
Red blood cell treatment with xanthine
dehydrogenase/oxidase and hypoxanthine 
Human RBC were exposed to 1.5 mM hypoxanthine in
the presence of xanthine oxidase (0.8 U/mL) at 37°C for up
to 6 h in a shaking water bath, as reported elsewhere.37
Proteomic analyses 
Leukocyte-reduced human RBC from healthy donor vol-
unteers were washed five times in phosphate-buffered
saline prior to lysis in distilled water with sonication.
Proteomic analyses of RBC membranes and cytosols were
performed as described elsewhere38 using 30 mg of protein
per time point and a 4-12% gradient SDS-PAGE gel.39 Bands
were reduced, alkylated, trypsin digested, and then ana-
lyzed by nanoUHPLC-MS/MS (nanoEasy LC II coupled to
a Q Exactive HF – Thermo Fisher, Bremen, Germany).
Alternatively, RBC cytosolic proteins were depleted of
hemoglobin using HemovoidTM (Biotech support group,
Monmouth Junction, NJ, USA), prior to high-pH reversed
phase fractionation;40 64 fractions were collected (32 each
for cytosol and membranes) over a 3 h gradient, prior to
nano-UHPLC-MS/MS proteomics, as described previously.9
Error tolerant searches were performed using Mascot (v.
2.4) against the human UniprotKB database (release date
2015.1.8), including decoy sequences (cysteine car-
bamidomethylation and methionine oxidation set as fixed
and variable modifications, respectively). Mass tolerances
for membrane and vesicle data were set to ±15 ppm for pre-
cursor ions and ±0.01 Da for fragment ions. For all Mascot
search results, peptide spectral matches were filtered at a
95% confidence threshold (excluding matches with an
expectation value >0.05).
Sample processing and metabolite extraction
RBC were separated by centrifugation (10 min at 4ºC
and 2500 x g) and then 50 mL were extracted in 450 mL of
lysis buffer (methanol:acetonitrile:water 5:3:2) via ice
cold extraction by vortexing for 30 min at 4ºC.14,41
Insoluble proteins were pelleted by centrifugation (10
min at 4ºC and 10,000 x g) and supernatants were collect-
ed and stored at -80°C until analysis.
Ultrahigh performance liquid chromatography – mass
spectrometry metabolomics 
Analyses were performed using a Vanquish UHPLC sys-
tem coupled online to a Q Exactive mass spectrometer
(Thermo Fisher, Bremen, Germany). Samples were resolved
over a Kinetex C18 column (2.1 x 150 mm, 1.7 µm;
Phenomenex, Torrance, CA, USA) at 25ºC using a 3 min
isocratic condition of 5% acetonitrile, 95% water, and 0.1%
formic acid flowing at 250 mL/min,42 or using a 9 min gradi-
ent at 400 mL/min from 5-95% B (A: water/0.1% formic
acid; B: acetonitrile/0.1% formic acid).14 MS analysis and
data processing were performed as described elsewhere.14
Metabolite assignments, absolute quantification against
heavy labeled internal standards and calibration curves of
external standards (Cambridge Isotopes, Tewksbury, MA,
USA), isotopologue distributions, and correction for expect-
ed natural abundances of 13C isotopes were performed
using MAVEN (Princeton, NJ, USA), as already described.42
Absolute quantities of hypoxanthine were determined
using the following formula:
HypoxanthineAbsoluteQuant = (Integrated Peak AreaLight /
Integrated Peak AreaHeavy) x ConcentrationHeavy x 10 
where 10 is the dilution factor
Graphs and statistical analyses (t-test, repeated measures
ANOVA, or Spearman correlation) were prepared with
GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA,
USA).
Results 
Hypoxanthine accumulates during murine and human
red blood cell storage and negatively correlates with
post-transfusion recovery 
Intracellular and supernatant hypoxanthine levels pro-
gressively increase during standard storage of human RBC
in AS-3 (Figure 1A), reaching concentrations as high as 450
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mM and 800 mM, respectively, consistent with previous
studies using other storage solutions (e.g. SAGM).16,31
Quantitative hypoxanthine levels also allow discrimina-
tion between three metabolic phases of the RBC storage
lesion, as previously determined by receiver operating
characteristic (ROC) curves for RBC stored in SAGM.28
Here we show similar results for RBC stored in AS-3
(Figure 1B) on the basis of absolute quantitative measure-
ments, confirming and improving on the previous relative
quantitative measurements (i.e., arbitrary units).28
Deamination of RBC purines (Figure 1C) by purine
deaminases, such as AMPD, was initially described in the
1930s.43 More recent studies focused on the role of oxida-
tive stress in activating AMPD3, the RBC-specific
isoform.44 Consistent with observations in humans,
hypoxanthine levels were reported to increase in stored
C57BL/6J mouse RBC samples, without separation of cells
and supernatants;45 here we confirmed and extended this
observation by separately analyzing stored mouse RBC
and supernatants (Figure 2A). Interestingly, in contrast to
the human samples (Figure 1A), supernatants of mouse
RBC stored in AS-3 contained less hypoxanthine at the
end of storage as compared to RBC cytosol (Figure 1B). 
Despite increased understanding of the storage lesion,2
it remains controversial whether the (metabolic) storage
lesion in vitro holds any clinical relevance.3 PTR is – accord-
ing to regulations of the US Food and Drug
Administration – a standard measure of RBC storage qual-
ity with potential clinical relevance, in that the capacity to
circulate in the recipient’s bloodstream is a necessary (but
not sufficient) requirement for RBC to function in vivo. We,
therefore, performed 24 h PTR studies in mice and
humans, and compared these results with hypoxanthine
levels (Figure 2B). To this end, stored RBC from 79 mice of
14 different strains were assayed for hypoxanthine levels
and PTR studies were completed following transfusion
into C57BL6 recipients. As a result, a significant negative
correlation was found (median of all strains P<0.0001; r =
-0.87 Spearman; r = -0.88 for 8 out of 14 strains) (Figure
2C). Similarly, pre-transfusion hypoxanthine levels in
stored human RBC from healthy volunteers (n=52, trans-
fused RBC from week 1-6) negatively correlated with PTR
in the autologous transfusion setting (P=0.0018, r = -0.43
Spearman) (Figure 2D).
Oxygen saturation affects purine deamination in vivo
and ex vivo
Refrigerated RBC storage promotes oxidative stress,6
which is mitigated, in part, by decreasing SO2 during
hypoxic storage.9 Strikingly, SO2 levels in 977 freshly
donated units assayed within 8 h of donation and standard
processing were widely distributed on storage day 1
(Online Supplementary Figure S1), ranging from 5% to 95%.
This indicates that SO2 at donation is currently an uncon-
trolled variable in the donor population with the potential
to affect RBC purine deamination. We, therefore, per-
formed a series of experiments to determine whether
exposure to hypoxia or hyperoxia in vitro or in vivo affected
purine deamination and hypoxanthine accumulation in
human and mouse RBC. Notably, exposure of healthy vol-
unteers (and good acclimatizers) to high altitude hypoxia
(>5000 m for up to 7 days) (Figure 3A) led to significant
decreases in RBC hypoxanthine levels, even by 3 h
(ALT1am, P=0.02) and 8 h (ALT1pm, P=0.0002) after
ascent, which were even greater after 7 days at high alti-
tude (P=8.9x10-5) (Figure 3B). Similarly, exposure of
C57BL/6J mice (n=6) to hypobaric hypoxia (8% O2 for up
to 8 h) led to significant (P<0.01) decreases in RBC hypo -
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Figure 1. Hypoxanthine is a metabol-
ic marker of the red blood cell stor-
age lesion. (A) Intracellular (left) and
supernatant (right) levels of hypoxan-
thine increase in packed RBC stored
in the presence of AS-3. All data
points shown on the x axes were test-
ed and interpolated with third order
polynomial curves (not assuming lin-
ear evolution of hypoxanthine accu-
mulation during storage) and median
± ranges (n=4) are shown (dark blue
lines and light blue areas, respective-
ly). (B) ROC curves identify hypoxan-
thine as a biomarker of the three
metabolic stages of stored RBC with
extreme sensitivity and specificity (as
indicated by high true positive and
low false positive rates), confirming
previous observations in SAGM.25 A
simplified overview of purine catabo-
lism and oxidation intermediates is
outlined. Structures are provided for
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Figure 2. Hypoxanthine negatively correlates with post-trasfusion recovery of using mouse and human red blood cells. (A) Hypoxanthine accumulation is observed
in stored C57BL/6J mouse RBC. (B) Transfusion into GFP-RBC mouse recipients (sorting of fluorescence negative RBC) or 51Cr labeling of human RBC was performed
to determine 24 h PTR in mice (n=79) and human volunteers (n=52), whereas paired samples were used to determine hypoxanthine levels. (C, D) Negative correla-
tions were observed for mouse (C) and human RBC hypoxanthine levels and 24 h PTR. Linear and quadratic Spearman correlations as well as their levels of signifi-
cance are shown for mouse (median across strains) and (D) human data. 
Figure 3. Hypoxanthine levels decrease in
human and mouse red blood cells exposed to
hypoxia in vivo and in vitro. (A) RBC were collect-
ed from 21 healthy volunteers at sea level (SL)
and within 3 or >8 h after exposure to high alti-
tude hypoxia on day 1 (ALT1 am and pm, respec-
tively), and at 7 days (ALT7) after exposure to
high altitude (>5000 m) hypoxia. (B)
Hypoxanthine levels decreased significantly in
human RBC within hours of exposure to high alti-
tude hypoxia (x axis labels consistent with
description of panel A). (C) C57BL/6J mice (n=6)
were exposed to normoxia or 8% oxygen for 3 h,
resulting in decreases in RBC levels of hypoxan-
thine, a phenomenon accompanied by
decreased IMP and increased AMP/IMP ratios
(Online Supplementary Figure S1). (D) RBC were
collected from C57BL/6J mice prior to in vitro
storage in AS-3 for up to 2 weeks under normox-








xanthine levels (Figure 3C), while boosting AMP/IMP
ratios (Online Supplementary Figure S2). In addition, when
mouse RBC (n=5) were stored for up to 2 weeks under nor-
moxic or hypoxic (8% O2) conditions, lower hypoxanthine
levels were seen with hypoxia (Figure 3D). Analogously,
human RBC (n=4) were stored under controlled SO2 condi-
tions, ranging from hyperoxia (SO2 >95%), to normoxia
(no SO2 control), to hypoxia (SO2 = 20%, 10%, 5% or
<3%) (Figure 4A). Although all conditions induced storage-
dependent increases in cellular and supernatant hypoxan-
thine levels, hypoxic RBC (independently of the degree of
hypoxia) resulted in significantly (P<0.01) lower levels of
intracellular hypoxanthine from storage day 14 onwards
(Figure 4B – left panel). Supernatant hypoxanthine levels
were significantly lower in all hypoxic RBC after storage
day 14 (Figure 4B – right panel). No significant effect of
hyperoxia (SO2 >95%) was observed, except for higher
than control (P<0.05) supernatant hypoxanthine levels at
storage day 7, consistent with previous observations that
SO2 can increase to >95% by storage week 3 in normoxic
(uncontrolled SO2) RBC with day 0 SO2 >60% (though
units in this study were agitated biweekly after sampling).9
Purine salvage and deamination in human and mouse
red blood cells as a function of oxidative stress
In the previous section we showed that oxygen satura-
tion affects hypoxanthine accumulation in human and
mouse RBC in vitro and in vivo. Mechanistically, hypoxia-
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366 haematologica | 2018; 103(2)
Figure 4. Effects of oxygene saturation on hypoxanthine accumulation during refrigerated storage. (A) Human RBC were donated by healthy volunteers (n=4) prior
to refrigerated storage in AS-3 under control (normoxic), hyperoxic (SO2>95%), or hypoxic (SO2 = 20%, 10%, 5% or <3%) conditions for up to 42 days.  (B) Hypoxanthine
concentration was determined in cells and supernatants, with significant decreases in the presence of hypoxia. All data points shown on the x axes were tested and
interpolated with third order polynomial curves (not assuming linear evolution of hypoxanthine accumulation during storage) and medians ± ranges (n=4) are shown
(dark blue lines and light blue areas, respectively).
Figure 5. Purine salvage and deamina-
tion reactions. (A) Purine salvage and
deamination reactions are catalyzed by
adenylosuccinate synthase (ADSS - 1)
and adenylosuccinate lyase (ASL – 2),
and by adenosine monophosphate
deaminase (AMPD3 - 3), respectively. (B)
Deep proteomic analyses identified
ADSS, ASL and AMPD3 in human RBC, in
contrast to prior studies indicating the
absence of ADSS in mature human
RBC.42
BA
dependent decreases in purine deamination may be
explained either by decreases in AMPD3 activity or
increases in salvage reactions, including those catalyzed
by adenylosuccinate synthetase (ADSS) and adenylosuc-
cinate lyase (ASL) (Figure 5A). Deep proteomic analyses
of RBC from healthy donor volunteers identified
AMPD3, ASL (also confirmed by Western blot in mouse
RBC) (Online Supplementary Figure S3), and traces of ADSS
in human RBC (sequence coverage shown in Figure 5B),
despite classic literature indicating the absence of ADSS
in mature human RBC.46 Mascot scores for peptide hits
for each one of these proteins are reported in Online
Supplementary Table S1.
AMPD3 activity is stimulated by oxidative stress,44 an
observation supported herein by metabolomics evidence
demonstrating increased inosine monophosphate (IMP)
and hypoxanthine, and decreased AMP and AMP/IMP
ratios, in human RBC exposed to hydrogen peroxide-gen-
erating xanthine dehydrogenase/oxidase (XDH) in the
presence of hypoxanthine (at levels similar to those
observed in RBC supernatants at the end of storage; i.e.,
the high mM to low mM range) (Figure 6A). 
G6PD is the rate-limiting enzyme of the pentose phos-
phate pathway (PPP), which is essential for RBC redox
homeostasis because it generates reducing cofactors (i.e.,
NADPH) to recycle oxidized glutathione back to its
reduced form. Thus, we hypothesized that refrigerated
storage of RBC from G6PD-deficient subjects increases
oxidative stress and would result in increased hypoxan-
thine levels. In our hands, refrigerated storage of RBC
from G6PD-deficient volunteers (n=6; Mediterranean
variant, <10% residual activity, non-hemolytic) demon-
strated significant increases in hypoxanthine levels in
comparison to controls, beginning after storage day 14
(Figure 6B). 
Hypoxia prevents hypoxanthine accumulation by 
deregulating adenosine monophosphate deamination
rather than by  promoting salvage reactions
Based on our observations, oxidative stress promoted
purine deamination and hypoxanthine accumulation in
RBC after: (i) incubation with xanthine dehydrogenase in
the presence of hypoxanthine, and (ii) refrigerated storage,
particularly in the case of G6PD-deficient donors.
Conversely, hypoxia in vivo and in vitro has a beneficial role
in mice and humans, by preventing purine deamination
and hypoxanthine accumulation. Enzymes involved in sal-
vage reactions (ADSS and ASL) and purine deamination
(AMPD3) have been identified in mature RBC via deep
proteomic measurements, suggesting that either pathway
may be susceptible to oxidative stress and/or hypoxia. To
expand on these steady state observations to test actual
fluxes through these pathways, human RBC were incu-
bated with 13C1-aspartate for 6 h to determine the rate of
“heavy” fumarate accumulation through salvage reactions
(Figure 7A). Accumulation of isotopologue +1 of fumarate
from aspartate may be alternatively explained by
fumarate hydratase and malate dehydrogenase activity on
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Figure 6. Oxidative injury or
impairment of the antioxidant
capacity in glucose-6-phos-
phate dehydrogenase-defi-
cient red blood cells enhances
purine deamination. (A)
Exposure of human RBC to pro-
oxidant treatment with hypox-
anthine plus xanthine dehydro-
genase (XDH) for up to 6 h
enhances AMP deamination to
IMP accompanied by accumu-
lation of hypoxanthine. (B)
Human RBC from G6PD-defi-
cient donors (Mediterranean
variant, <10% residual activity
of the enzyme) were stored for
up to 42 days, showing signifi-
cantly higher levels of hypoxan-
thine throughout the whole
storage period (analyses were
performed on whole trans-
fusates: cells + supernatants)
(median + ranges for RBC from
G6PD donors are plotted  as a
solid red line and light red
area, respectively). In (B), all
data points shown on the x axis
were tested and interpolated
with third order polynomial
curves (not assuming linear
evolution of hypoxanthine
accumulation during storage).
oxaloacetate derived from transamination of aspartate,
reactions possible in mature erythrocytes.47 Although
heavy aspartate consumption was faster in hypoxic RBC,
the rates of 13C-fumarate generation were not sufficiently
higher than in normoxic controls to explain the observed
increases in AMP/IMP ratios in hypoxic RBC (e.g., only
~26-30% of fumarate was labeled at 6 h after incubation
with heavy aspartate in both normoxic and hypoxic
groups). In parallel, human RBC were incubated for 6 h
with 13C5-adenosine to determine the rate of purine deam-
ination (Figure 7B), demonstrating significantly decreased
rates of IMP generation in hypoxic RBC. Analogously,
refrigerated storage of mouse RBC under hypoxic condi-
tions prevented purine deamination, as demonstrated by
13C5-adenosine tracing experiments (Figure 7C). Finally,
incubating mouse RBC with deoxycoformycin, an adeno-
sine and AMPD inhibitor, mimicked the hypoxic pheno-
type in terms of purine deamination and increased
AMP/IMP ratios (Figure 7D). Thus, these results suggest
that hypoxanthine accumulation, in this context, is prima-
rily due to purine deamination.
Discussion
Recently, we and others identified hypoxanthine19,28 as a
potential metabolic marker of the RBC storage lesion with
potential clinical implications. Indeed, circulating hypo -
xanthine can be readily converted to xanthine and urate
by reactions that generate hydrogen peroxide.48 For exam-
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Figure 7. Tracing experiments reveal hypoxic inhibition of purine deamination, rather than hypoxic increases in purine salvage. (A, B) Human RBC were incubated
with (A) 13C1-aspartate to determine the rate of fumarate generation (salvage) and with (B) 13C5-adenosine to determine the rate of AMP deamination. (C) 13C5-adenosine
tracing experiments demonstrated that in vitro storage of mouse RBC under hypoxic conditions prevents purine deamination. (D) Incubation of mouse RBC with deoxy-





ple, ischemic accumulation of plasma hypoxanthine can
fuel pro-oxidant reactions following reperfusion.49 For this
reason, rejuvenated RBC need to be washed prior to trans-
fusion to avoid excess infusion of inosine and its metabol-
ic product, hypoxanthine.50 By quantifying RBC and
supernatant hypoxanthine levels during storage in AS-3,
we confirmed and extended previous observations made
in RBC stored in SAGM16,19 concerning the role of this
metabolite as a reliable marker of the storage lesion. Thus,
we correlated pre-transfusion in vitro hypoxanthine levels
in mouse and human RBC with PTR determinations in
vivo; the latter is one of the key US Food and Drug
Administration’s criteria for approving novel RBC storage
methods.24 Because RBC must circulate to perform their
therapeutic function, we believe that – provided the evi-
dence in mice and preliminary findings in humans report-
ed here are further prospectively validated - this observa-
tion may support the clinical relevance of hypoxanthine as
a potential predictor of transfusion outcomes. In addition,
despite intrinsic metabolic differences in purine catabo-
lism between rodents and humans (e.g., the former
express functional uricase51 which may contribute to
explaining the minor inter-species difference in hypoxan-
thine levels in cells and supernatants observed here),
hypoxanthine levels in vitro correlated negatively with PTR
in vivo in both mice and - to a lesser, albeit significant,
extent - humans, further documenting the relevance of
animal models in transfusion medicine research.52
During the last few decades, retrospective clinical stud-
ies,53 coupled with improved mechanistic understanding
of the RBC storage lesion,2 have prompted the field of
transfusion medicine to question the safety and efficacy of
stored RBC. Recent prospective clinical trial evidence reas-
sured the field about the non-inferiority of the current
standard of care when compared to transfusion of fresh
units.20 Nonetheless, transfusion of RBC stored for more
than 5 weeks significantly increases circulating non-trans-
ferrin-bound iron levels,21 potentially increasing the risk of
complications in certain categories of recipients.22 Omics
markers of the storage lesion were recently identified,28,29
with the goal of benchmarking novel strategies or additive
solutions to improve RBC storage quality. However, the
disconnect between the well-established metabolic stor-
age abnormalities and the reassuring clinical trial evidence
prompted the field to question the relevance of metabolic
markers of RBC storage age with respect to transfusion
outcomes, a critical issue extensively discussed by many
key opinion leaders.54 For example, over the past five
decades, biochemical studies clearly documented that
impairment of RBC energy and redox homeostasis (espe-
cially regarding levels of ATP and reduced glutathione)
negatively affects RBC recovery in vivo,55 along with oxy-
gen transport and delivery. Interestingly RBC levels of ATP
and glutathione (as well as levels of at least 24 metabolites
correlating with those of RBC ATP) are heritable traits,56
like hemolysis in vitro, although hemolysis does not corre-
late with pre-transfusion levels of these metabolites.57
Thus, it has been argued that these metabolites do not
accurately predict transfusion outcomes likely because, as
historically appreciated for 2,3-DPG,58,59 their levels are
restored by 50% within the first 4 h after transfusion and
return to normal by 72 h. However, these rates may not be
sufficient to restore optimal tissue oxygenation in critical-
ly ill recipients who require massive transfusion, even
though tissue oxygenation and systemic acidosis are effi-
ciently restored by current resuscitation strategies.
Mechanistically (Figure 8), we propose that refrigerated
RBC storage promotes, among many cascades of events,2–5
the activation of AMPD3 (the RBC-specific isoform of
AMPD, and the only one identified here using deep pro-
teomics). AMPD3 can be activated by increases in intracel-
lular ROS44 and calcium,60,61 along with decreases in intra-
cellular pH;62,63 in contrast, increases in 2,3-DPG downreg-
ulate AMPD3 activity.63 Notably, refrigerated RBC storage,
especially after storage day 14, leads to increases in ROS
and intracellular calcium, and decreases in pH and 2,3-
DPG,2,6 all of which can combine to activate AMPD3, as
our steady state and metabolic flux results suggest. This
concept is supported by the positive effects of hypoxic
storage, including decreased purine deamination leading
to decreased hypoxanthine levels. Interestingly, AMPD3
activation shortens RBC lifespan64 by converting AMP into
IMP, thereby contributing to adenine nucleotide dysregu-
lation in RBC from normal individuals and those with
sickle cell anemia. Conversely, the human enzymopathy
of AMPD3 deficiency does not produce any relevant phe-
notype except for inducing increased levels of RBC ATP
and ADP, thereby promoting a hypometabolic state with
decreased hemoglobin oxygen affinity.65,66
Being at the crossroads between energy generation and
redox metabolism, AMPD3 represents an ideal target for
modulating RBC metabolism during refrigerated storage.
Here we show that oxygen saturation and oxidative stress
during refrigerated storage modulate purine deamination
in human and mouse RBC in vivo and in vitro. This is rele-
vant because of the unexpected widespread distribution of
oxygen saturation of freshly donated human RBC within
8 h after donation and routine normoxic processing, sug-
gesting that oxygen levels may represent a relevant vari-
able that can be controlled to enhance the uniformity of
stored blood.35 In addition, RBC from human G6PD-defi-
cient donors - characterized by increased basal and stor-
age-dependent oxidative stress67 - produce higher levels of
hypoxanthine during refrigerated storage as compared to
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Figure 8. Proposed mechanism of the effect of hypoxia on the purine salvage path-
way. RBC storage or oxidative stress promotes activation of RBC AMPD3, which in
turn catalyzes purine deamination. This phenomenon is in part counteracted by
RBC exposure to hypoxia in vivo or ex vivo, which phenocopies the pharmacological
inhibition of purine deaminases.
controls. G6PD activity in stored human RBC was report-
ed to decline in SAGM additives,67,68 though no notable
changes in G6PD activity69 or PPP fluxes, as determined by
[1,2,3-13C3]glucose tracing experiments,9 were noted in AS-3
stored RBC. In addition, although human G6PD activity is
linked to gender (i.e., the G6PD gene is on chromosome
X) and decreases with age,70 correlations between donor
age or gender with transfusion outcomes are controver-
sial.71,72 Notably, diamide treatment of G6PD-deficient
RBC induced increases in AMP, IMP and hypoxanthine,73
consistent with our results with human G6PD-deficient
RBC.67 In human G6PD-deficient RBC, increases in AMP
were explained by the inability to reduce oxidized glu-
tathione using PPP-derived NADPH, which, in turn,
required increases in ATP-consuming de novo GSH synthe-
sis.73
Tracing experiments with 13C1-aspartate and 13C5-adeno-
sine show that hypoxic storage of RBC induces decreased
AMPD3 activity, rather than increased purine salvage. The
deep proteomic analyses identified traces of ADSS and
ASL, and residual activity of the salvage pathway in
mature RBC, thereby extending prior findings.43,46
Pharmacological inhibition of purine deaminase activity in
normoxic RBC using deoxycoformycin mimicked the ben-
efits of hypoxic storage, suggesting that manipulating the
purinergic signaling axis using novel storage additives may
improve RBC storage quality by enhancing energy pro-
duction and redox homeostasis,74 similar to the metabolic
adaptations of RBC to high altitude hypoxia.75
Finally, it is worth noting that, historically, circulating
hypoxanthine levels (not RBC levels) have been suggested
as a marker of hypoxia.49 Plasma hypoxanthine, under
hypoxic conditions (e.g. high altitude or ischemia), may
affect the severity of the reperfusion injury during its con-
version to urate, a reaction that simultaneously generates
pro-oxidant hydrogen peroxide.49 Similarly, accumulation
of dicarboxylates and excess activation of salvage reac-
tions in response to constrained oxygen availability were
identified as mediators of oxidative reperfusion injury in
mitochondria-proficient cells.76 The apparent disconnect
between the present findings and the literature is recon-
ciled by the observation that hypoxanthine levels in mito-
chondria-free RBC are not necessarily related to plasma
levels of this metabolite (especially in the platelet and
white blood cell-filtered environment of a packed RBC
unit); for example, this is observed in underwater mam-
mals, such as dolphins, which are constantly exposed to
prolonged periods of hypoxia.77 Thus, hypoxanthine levels
in isolated RBC (as in stored RBC units), or in circulating
RBC after exposure to high altitude, may not directly cor-
relate with plasma hypoxanthine levels.  
Conclusion
Hypoxanthine is a marker of the RBC storage lesion in
mice and humans in vitro; in addition, it correlates with
PTR results in vivo in mice and, preliminarily, in humans -
though additional validation in larger cohorts including
poor “recoverers” will be necessary. Storage-dependent
increases in cytosolic and supernatant purine deamination
during human and mouse RBC storage are ameliorated by
hypoxia. In addition, oxidative stress, induced by exoge-
nously added pro-oxidants or in response to PPP shut-
down in G6PD-deficient human RBC, promotes purine
deamination and increases intracellular levels of hypoxan-
thine. Pharmacological inhibition and metabolomics
experiments with stable isotope tracers suggest that
decreased AMPD3 activity provides a potential mechanis-
tic explanation of the benefits (i.e., decreased purine
deamination) associated with RBC exposure to hypoxia in
vivo and in vitro. Future studies are needed to investigate
whether the correlation between pre-transfusion levels of
hypoxanthine in vitro and PTR results in vivo could be
explained by the role that this metabolite plays as a sub-
strate for generating hydrogen peroxide in the circulatory
system of the transfusion recipient.
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